Guoshuai Xu

Guoshuai Xu


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2024 in Medicine
Verified
Journal Article
Open access
NYNan Yao
Nan Yao
WLWenqiang Li
Wenqiang Li
NDNing Duan
Ning Duan
GXGuoshuai Xu
Guoshuai Xu
GYGuoyong Yu
Guoyong Yu
Jun QuJun Qu
Jun Qu
Gastrointestinal (GI) cancers pose a significant challenge due to high prevalence and mortality. While advancements in detection and conventional treatments have been made, prognosis often remains poor, particularly for advanced-stage cancers. Immunotherapy has emerged as a transformative approach, leveraging the body immune system against cancer, including immune checkpoint inhibitors (ICIs), cancer vaccines, and adoptive cell transfer. These modalities have shown promise, achieving sustained responses and improved survival in some patients. However, their efficacy in GI cancers is less pronounced, hindered by drug resistance mechanisms that are either intrinsic or acquired over time. This review examines the latest understanding of immunotherapy in GI cancers, focusing on ICIs, cancer vaccines, and adoptive cell transfer, along with their associated outcomes and limitations. It delves into the mechanisms behind drug resistance, including alterations in immune checkpoints, the immunosuppressive tumor microenvironment, and genetic/epigenetic changes. The role of the gut microbiome is also considered as an emerging factor in resistance. To combat drug resistance, strategies such as enhancing immune response, targeting the tumor microenvironment, and modulating resistance mechanisms are explored. The review underscores the potential of ferroptosis induction as a novel approach. Looking forward, it highlights the need for personalized immunotherapies, understanding the influence of the gut microbiome, and further exploration of ferroptosis in overcoming resistance. While challenges persist, the continuous evolution in GI cancer immunotherapy research promises innovative treatments that could significantly improve patient outcomes.

29 October 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
Sin Hang ChengSin Hang Cheng
Sin Hang Cheng
YZYin Zhang
Yin Zhang
WLWenqiang Li
Wenqiang Li
GXGuoshuai Xu
Guoshuai Xu
Jun QuJun Qu
Jun Qu
The gut microbiome has emerged as a key modulator of therapeutic responses in gastrointestinal cancers. This narrative review critically summarizes how specific pathogenic bacteria—including Fusobacterium nucleatum, Bacteroides fragilis, and Gammaproteobacteria—have been implicated in chemoresistance through autophagy activation, suppression of endoplasmic reticulum stress-mediated cell death, inhibition of pyroptosis, induction of cancer-cell quiescence, and direct drug metabolism. In immunotherapy, the microbiome profoundly influences immune checkpoint inhibitor efficacy; Akkermansia muciniphila and Clostridium butyricum enhance anti-tumor immunity via the cGAS-STING pathway and the secD/GRP78/IL-6 axis, while microbial metabolites such as succinate, 4-hydroxyphenylacetic acid, and spatially depleted butyrate promote resistance through CD8+ T-cell exhaustion and immunosuppressive cell recruitment. In gastric cancer, Helicobacter pylori and non-Helicobacter gastric microbiota shape chemotherapy and immunotherapy responses; in hepatocellular carcinoma, the gut–liver axis and bile acid metabolism influence immune checkpoint blockade; and in pancreatic ductal adenocarcinoma, intratumoral Gammaproteobacteria and metabolites such as trimethylamine N-oxide and indole-3-acetic acid modulate gemcitabine resistance and immunotherapy efficacy. We further evaluate emerging microbiome-targeted strategies including fecal microbiota transplantation, engineered probiotics, and bacteriophage therapy, and discuss challenges in clinical translation. By elucidating the molecular mechanisms of microbiome-mediated therapy modulation, we propose a hypothesis-generating, evidence-graded framework for future prospective validation in microbiome-guided precision oncology.